ArticleBMC cancer2026
Efficacy and safety of Y90 radioembolization combined with targeted therapy and immunotherapy in patients with unresectable hepatocellular carcinoma: a dual-center, retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPatients with unresectable hepatocellular carcinoma (uHCC) have a poor prognosis and limited treatment options. The combination of transarterial radioembolization (TARE) with yttrium-90 (Y90), targeted therapy, and immunotherapy represents a novel integrated approach, yet real-world evidence regarding its efficacy and safety remains scarce.
methodsIn this dual-center retrospective study, 32 patients with uHCC who received combined therapy with TARE, a targeted agent and an immune checkpoint inhibitor were enrolled. Tumor response was evaluated according to mRECIST and RECIST 1.1. Survival outcomes were analyzed using the Kaplan–Meier method, and prognostic factors were identified through Cox regression analyses.
resultsAmong the 32 patients (87.5% male, 93.8% HBV-related), 71.9% had a maximum tumor diameter ≥10 cm, 53.1% had Vp3/4 portal vein tumor thrombosis, and 31.2% had extrahepatic metastasis. The objective response rate was 71.9% by mRECIST and 50.0% by RECIST 1.1. After a median follow-up of 12 months (IQR: 9–14.3), median progression-free survival was 10.5 months (95% CI: 7.4–13.6), and median overall survival was 17.0 months (95% CI: 11.5–22.5). A baseline alpha-fetoprotein level ≥400 ng/mL was identified as an independent adverse prognostic factor for both progression-free survival (HR = 2.755, p = 0.033) and overall survival (HR = 4.189, p = 0.029). Grade 3–4 treatment-related adverse events occurred in 43.8% of patients, with no treatment-related deaths.
conclusionIn conclusion, this real-world study provides preliminary evidence that the triple-modality regimen of TARE, targeted therapy, and immunotherapy has encouraging antitumor activity and a manageable safety profile in patients with uHCC, suggesting its potential as a feasible treatment strategy for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.